Randomized, double-blind trial of preoperative pregabalin versus placebo to improve quality of recovery after breast cancer surgery
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
INTRODUCTION: Surgery remains one of the most important treatments for breast cancer. In this context, the quality of postoperative recovery has become a key concern. Adequate control of acute pain is essential to optimize patient comfort and recovery. Pregabalin may contribute to this goal by preventing central sensitization and reducing perioperative anxiety. OBJECTIVES: To evaluate the effect of perioperative pregabalin versus placebo on postoperative recovery quality in patients undergoing breast cancer surgery. METHOD: In this randomized controlled trial, 92 patients received either pregabalin (150 mg orally, 1 hour before surgery) or a matching placebo, both prepared in identical capsules. The primary outcome was the QoR-15 score measured preoperatively, and at 24 and 48 hours postoperatively. The 24- and 48-hour assessments were conducted via telephone. The QoR-15 is a validated instrument that assesses the quality of recovery, with total scores ranging from 0 (very poor recovery) to 150 (excellent recovery). Secondary outcomes included opioid consumption, pain scores, incidence of nausea and vomiting, and lengths of stay in the Post-Anesthesia Care Unit (PACU) and hospital. An exploratory analysis of longitudinal changes in QoR-15 scores within each group was also performed. Analyses were performed per protocol. RESULTS: Eighty-four patients completed the study. There were no differences in overall QoR-15 score between the groups at any of the three assessment time points (preoperative, 24h, and 48h). In the exploratory longitudinal within-group analysis, better maintenance of recovery quality was observed in the pregabalin group compared with baseline, with medians (IQR) of 138 (122.3-145), 132.5 (125.8-135.3), and 134 (131.5-136) [p = 0.006 between 24h and 48h]. In the placebo group, the medians (IQR) were 140 (128-145.3), 129 (126-134.3), and 134 (126.8-136.3) [p = 0.002 between pre and 24h; p = 0.026 between pre and 48h]. CONCLUSION: Although exploratory analysis showed a trend toward improvement within the pregabalin group, there was no significant difference in QoR-15 scores between groups.
Fields of Study & Subjects
Anesthesia and Pain Management
Enhanced Recovery After Surgery
Nausea and vomiting management
Publication details
- Journal / source
- Brazilian Journal of Anesthesiology (English Edition)
- Volume
- 76
- Issue
- 3
- Pages
- 844749–844749
- Publication date
- 26 March 2026
- Language
- EN